FairJourney Bio (“FJBio”), a global antibody discovery expert, has entered into a partnership with AbTherx, Inc. to bring transgenic mouse-based antibody discovery in-house. The agreement gives the company access to AbTherx’s Atlas™ Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technology, completing a discovery route that partners can run end-to-end entirely within FJBio’s integrated workflow.
The partnership enables the program to move as a single effort, from vaccination through single B cell screening and optimization, to candidate stability assessment and cell line development, and is now executed by one team across FJBio’s global locations in Porto (Portugal), Cambridge (UK) and San Diego (USA). The goal is to reduce transitions between providers, shorten timelines, and enable leads built to develop, not just bind.
Atlas™ Mice comes from the team behind HuMAb Mouse®, whose technology has led to 13 commercially available antibody therapeutics. At FJBio, Atlas Mice feeds into the B-Cell Navigator platform, the company’s single B cell screening and developmental potential engine, so developmental potential is engineered into the molecule from the initial sequence, rather than being modified later.
AbTherx’s patent-pending FHD mice are engineered to deliver fully human antibodies with a broad range of human-like antibody responses by delivering VH and VK alleles representing more than 99% of the expressed human repertoire, and the cLC mice enable the creation of native-constructed bispecific and multispecific IgGs for ease of manufacturing and development. Atlas Mice has been validated through multiple independent direct studies and consistently outperforms traditional platforms. This technical advantage is confirmed by the use of a broader range of V genes, superior hit rates, enhanced antibody diversity and binding profiles, increased epitope coverage, and improved hybridoma and B cell stability.
Within FJBio’s workflow, this range of antibody diversity is carried through single B-cell screening and developability assessment, increasing the breadth of sources and yielding developable and manufacturable leads rather than hits that still need modification.
We are investing in enabling our partners’ programs to run within FJBio, from vaccination to feasibility assessment, without changing personnel. Tracking molecules with one team of scientists “under one roof” greatly increases the probability of success. ”
Dr. Werner Ranthaler, CEO of FairJourney Bio
“The AbTherx team has spent decades building, refining, and implementing the best technology for human antibody discovery, but even the most sophisticated platform requires knowledge and diligence to reach its full potential,” said Dan Rohrer, AbTherx Chief Technology Officer. “Combining our unique full human diversity and common light chain technology with Fairjourney Bio’s exceptional, quality-driven scientific team creates powerful synergies. Together, we are perfectly positioned to transform first-class science into high-performance therapeutic candidates.”
